ReviewTrends in parasitology2024
Mechanistic insights into liver-fluke-induced bile-duct cancer.
Review in Trends in parasitology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Silencing of Kinesin Light Chain 1 Suppresses Aggressive Phenotypes in Cholangiocarcinoma Cells Through Transcriptomic Alterations.International journal of molecular sciences · 2026Article
- A pathogenic CD8⁺ TNature communications · 2026Article
- Clonorchis sinensis excretory secretory products promote hepatic fibrosis through stimulating biliary epithelium to secrete IL-17A.PLoS neglected tropical diseases · 2026Article
- Impact of Community-Based Health Education and Sanitation Interventions onInternational journal of environmental research and public health · 2026Article
- Article
- The role of liver fluke invasion in the pathogenesis of cholangiocarcinoma.Clinical and experimental hepatology · 2026Review
- Gene Editing of a Carcinogenic Liver Fluke Tetraspanin Impairs Parasite Surface Biogenesis and Extracellular Vesicle Uptake by Human Host Cells.The Journal of infectious diseases · 2026Article
- Article
- Clonorchis sinensis and cholangiocarcinoma: molecular mechanisms and biomarker advances.Parasite (Paris, France) · 2026Review
- CRISPR/Cas genome editing, functional genomics, and diagnostics for parasitic helminths.International journal for parasitology · 2025Review
- Fluke-borne viruses are a risk factor for diseases caused by carcinogenic trematodes.bioRxiv : the preprint server for biology · 2025Article
- Impact of Clonorchis sinensis infection on long-term survival after curative resection for hepatocellular carcinoma: A multicenter cohort study.PLoS neglected tropical diseases · 2025Article
- Review
- Reassessing Schistosoma worms: the overlooked role in host pathology and disease elimination.Infectious diseases of poverty · 2025Review
- Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver fluke infection is a major risk for cholangiocarcinoma (CCA). It has been established that the Asian liver flukes, Clonorchis sinensis and Opisthorchis viverrini secrete growth factors, digestive enzymes, and extracellular vesicles (EVs) which contribute to abnormal cell development in the bile ducts where the worms reside. These secretions - combined with aberrant inflammation and repeated cycles of chronic wounding at the site of parasite attachment and grazing on the epithelium - promote biliary hyperplasia and fibrosis and ultimately malignant transformation. Application of post-genomic and gene-editing tools to the study of liver fluke immunobiology and pathogenesis has accelerated the discovery of essential virulence factors to which targeted therapies and diagnostics can be directed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.